Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EPS (Weighted Average and Diluted) (2020 - 2025)

Tg Therapeutics has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at $0.15 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.15 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $2.78 (up 1885.71% YoY), and the annual figure for FY2025 was $2.77, up 1746.67%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.15 at Tg Therapeutics, down from $2.43 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TGTX hit a ceiling of $2.43 in Q3 2025 and a floor of -$0.69 in Q1 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.1 (2023), compared with a mean of -$0.04.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 97.26% in 2024 and later soared 12050.0% in 2025.
  • Tg Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.65 in 2021, then rose by 12.45% to -$0.57 in 2022, then surged by 82.46% to -$0.1 in 2023, then soared by 250.0% to $0.15 in 2024, then dropped by 0.0% to $0.15 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.15 (Q4 2025), $2.43 (Q3 2025), and $0.17 (Q2 2025) per Business Quant data.